A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)

Trial Profile

A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2017

At a glance

  • Drugs Dusigitumab (Primary) ; Aromatase inhibitors
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Oct 2017.
    • 29 Nov 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top